In global cost-benefit terms, economists typically rate health care programs by the amount of disability they reduce per dollar. Historically, mental health interventions have scored poorly compared with efforts that save young lives, like neonatal care or treatment of diarrhea. A new analysis of mental health strategies in Ethiopia, for instance, found that treating schizophrenia with generic medications was about as cost-effective as treating heart disease with a combination of drugs, like aspirin and a statin — and much less cost-effective than treating depression or epilepsy. The findings, though preliminary, suggest that treating psychosis is relatively costly.
